CCIA
KPTI icon

Campbell & Co Investment Adviser’s Karyopharm Therapeutics KPTI Stock Holding History

Campbell & Co Investment Adviser’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,364
Closed -$680K – 281
2019
Q4 		$680K Buy
+2,364
New +$513K 0.21% 136

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Campbell & Co Investment Adviser's KPTI Position: Q1 2020 in Review

Campbell & Co Investment Adviser sold out of Karyopharm Therapeutics (KPTI) in Q1 2020, closing a stake of 2,364 shares — an estimated $680K sold.

Campbell & Co Investment Adviser first reported a position in KPTI in Q4 2019 and held it in 1 quarter. The position peaked at $680K in Q4 2019. 136 funds tracked by Wall St. Rank hold KPTI as of Q1 2020.

  • Campbell & Co Investment Adviser reported no remaining Karyopharm Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 2,364 Karyopharm Therapeutics shares in Q1 2020, an estimated $680K.
  • Campbell & Co Investment Adviser first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Karyopharm Therapeutics position peaked at $680K in Q4 2019.
  • 136 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2020.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2020, filed 29 Apr 2020.